Study guide

Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

Key Takeaways Explain This Topic AI

Tachypnoea supports suspicion of pneumonia but has limited specificity. Assess oxygenation, work of breathing, fever and focal findings together. Oral amoxicillin is first-line treatment for suspected non-severe bacterial CAP; select dose and duration using the applicable national or local guidance.

Persistent fever, worsening respiratory distress, or clinical non-response after 48 to 72 hours of appropriate antibiotic therapy mandates urgent evaluation for parapneumonic effusion or empyema via thoracic ultrasound.

Paediatric pleural drainage is guided by effusion size, respiratory compromise, clinical course, ultrasound complexity and frank pus. Low pH, low glucose and high LDH are typical infected-fluid findings, but routine biochemistry or a separate diagnostic tap is not required before drainage. Use a chest drain with fibrinolysis for significant loculated empyema; consider VATS for failure or selected complex disease.

Newborn IRT screening identifies babies needing CF diagnostic assessment; it does not itself diagnose CF. Sweat chloride ≥60 mmol/L supports diagnosis with a positive screen or compatible presentation, while intermediate results need specialist reassessment. Treat a first Pseudomonas isolate promptly with an appropriate eradication regimen even if the child is well.

Modern management of cystic fibrosis has been transformed by CFTR modulators, specifically the triple combination of elexacaftor, tezacaftor, and ivacaftor, which restores chloride channel function in patients harboring at least one F508del mutation.

Last updated: November 2026

Pediatric Community-Acquired Pneumonia (CAP)

Community-acquired pneumonia (CAP) remains a major cause of pediatric morbidity and hospital admission. Defining the causative organism is clinically challenging because invasive diagnostic procedures are rarely indicated in uncomplicated cases, and viral-bacterial co-infections occur in up to 30% to 50% of young children.

Age-Stratified Microbial Etiology

The likelihood of specific pathogens is strictly correlated with the child's age, immunological maturity, and vaccination status:

Age Group Predominant Bacterial Pathogens Viral & Atypical Pathogens Empirical First-Line Antibiotic

Neonates (<1 month) Group B Streptococcus (GBS), Escherichia coli , Listeria monocytogenes , Klebsiella Herpes simplex virus (HSV), Enterovirus, CMV IV Ampicillin + Gentamicin (or Cefotaxime)

Infants & Preschool (1 mo – 5 yr) Streptococcus pneumoniae (most common bacterial), Streptococcus pyogenes , Staphylococcus aureus Respiratory Syncytial Virus (RSV), Human Rhinovirus, Adenovirus, Parainfluenza Oral Amoxicillin , dose according to local CAP guidance

School-Age & Adolescents (≥5 yr) Streptococcus pneumoniae , Mycoplasma pneumoniae , Chlamydia pneumoniae Influenza A/B, Rhinovirus, Adenovirus Oral Amoxicillin (add Macrolide if atypical suspected)

Clinical Diagnosis and Examination Markers

Tachypnoea: Fast breathing is an important screening sign , particularly in young children, but does not reliably distinguish pneumonia on its own. Assess it with fever, oxygen saturation, work of breathing and focal chest findings. Use age-adjusted fast-breathing thresholds (WHO cut-offs for under-5s, with older-child thresholds varying by reference):

  • Age <2 months: ≥60 breaths/min
  • Age 2 to 11 months: ≥50 breaths/min
  • Age 12 to 59 months: ≥40 breaths/min
  • Age ≥5 years: ≥25 to 30 breaths/min

Auscultation & Percussion: Classic consolidation signs include focal late-inspiratory crackles, bronchial breathing (harsh, tubular breath sounds with equal inspiratory and expiratory phases), increased vocal resonance, and dullness to percussion. However, in infants and toddlers, auscultatory signs may be entirely absent or diffuse.

Referred Abdominal Pain: Lower lobe pneumonia frequently irritates the diaphragmatic pleura, referring pain to the anterior abdominal wall via lower intercostal nerves. Any child presenting with acute fever, right lower quadrant abdominal pain, and vomiting must have the respiratory rate counted and chest auscultated to rule out "abdominal pneumonia" before surgical exploration.

Radiological Indications: A routine chest radiograph is not recommended for children with mild, uncomplicated lower respiratory tract infections managed in the outpatient setting. CXR is indicated for: (1) hospitalized children with severe distress or hypoxemia, (2) diagnostic uncertainty or suspected foreign body, and (3) children failing to demonstrate clinical improvement after 48 to 72 hours of appropriate antimicrobial therapy.

First-Line Antimicrobial Strategy

Amoxicillin as First-Line Treatment: Oral amoxicillin is preferred for suspected non-severe bacterial CAP. Dose and duration depend on national guidance and local pneumococcal susceptibility. High-dose regimens use 80–90 mg/kg/day in 2 or 3 doses (maximum 1 g three times daily in some protocols). UK NICE 2025 instead uses age-banded doses and a 3-day course for ages 3 months–11 years with non-severe disease, no complications or underlying disease; younger infants and adolescents usually receive 5 days. Review if not improving and follow the applicable protocol.

Atypical Coverage: Do not routinely add a macrolide for preschool CAP, but do not exclude Mycoplasma pneumoniae on age alone: it can occur at 1–5 years. Consider atypical coverage when clinical suspicion or inadequate response warrants it. In school-age children (≥5 years) with persistent dry cough, headache, low-grade fevers, bilateral diffuse interstitial infiltrates, or extrapulmonary manifestations (e.g., erythema multiforme, cold agglutinin-mediated hemolytic anemia), add an oral macrolide (e.g., azithromycin 10 mg/kg/day on day 1, followed by 5 mg/kg/day for 4 days, or clarithromycin 15 mg/kg/day in 2 divided doses).

Severe Inpatient Pneumonia: Children requiring admission with oxygen dependency or inability to tolerate oral fluids are treated with intravenous ampicillin (50 mg/kg every 6 hours) or benzylpenicillin . If unimmunized against Hib or pneumococcus, or presenting with severe sepsis, administer IV cefotaxime (50 mg/kg every 6–8 hours) or ceftriaxone (80 mg/kg once daily) . If cavitary necrosis, pneumatoceles, or rapid deterioration suggests Staphylococcus aureus , add intravenous flucloxacillin (50 mg/kg every 6 hours) or vancomycin .

Complicated Pneumonia: Parapneumonic Effusion and Empyema

A parapneumonic effusion is an accumulation of pleural fluid secondary to adjacent pulmonary parenchymal infection, developing in up to 40% of hospitalized bacterial pneumonias. In approximately 5% to 10%, the collection progresses to empyema thoracis , characterized by macroscopic pus, positive microbial cultures, or dense fibrinopurulent loculations within the pleural space.

Pathophysiological Evolution

These fluid-chemistry patterns illustrate progressive infection. In children, routine pleural biochemistry is unnecessary for management; assess effusion size, respiratory compromise, ultrasound findings and clinical course rather than requiring a pH threshold before drainage.

Exudative Stage (Simple Parapneumonic Effusion): Rapid increase in pleural capillary permeability driven by parenchymal inflammation, producing clear, non-viscous exudative fluid. The fluid contains normal glucose, normal pH (>7.20), low LDH (<1,000 IU/L), and sterile cultures. Resolves promptly with systemic antibiotics alone.

Fibrinopurulent Stage (Complicated Effusion / Empyema): Bacterial invasion into the pleural space accelerates bacterial metabolism and neutrophil recruitment. Lysis of leukocytes elevates lactate dehydrogenase (LDH >1,000 IU/L) . Anaerobic leukocyte and bacterial glycolysis depletes pleural fluid glucose (<2.2 mmol/L / <40 mg/dL) and generates lactic acid and hydrogen ions, driving pleural fluid pH below 7.20 . Dense networks of fibrin are deposited on visceral and parietal pleura, organizing into thick septations and locked fluid loculations.

Organizing Stage: Fibroblasts migrate into the fibrin matrix, forming a dense, unyielding collagenous "pleural peel" that tethers the underlying lung, preventing pulmonary re-expansion (trapped lung).

Causative Microorganisms

Streptococcus pneumoniae remains the predominant pathogen worldwide (serotypes 1, 3 and 19A have been prominent causes, but all are included in PCV13; local patterns change with vaccination), followed by Streptococcus pyogenes (Group A Streptococcus) and Staphylococcus aureus (including Panton-Valentine leukocidin [PVL]-producing strains).

Clinical Suspicion and Ultrasound Diagnostics

Clinical Presentation: Suspect empyema when a child with pneumonia exhibits persistent or recrudescent high fever, worsening tachypnea, or clinical deterioration after 48 to 72 hours of appropriate parenteral antibiotic therapy .

Physical Examination: Stony dullness to percussion , profoundly reduced or absent breath sounds, decreased tactile vocal fremitus, asymmetric chest expansion, and scoliosis concave toward the affected hemithorax.

Thoracic Ultrasound (Gold Standard): Far superior to plain radiography and computed tomography (CT). Ultrasound distinguishes between consolidated lung parenchyma and pleural fluid, quantifies fluid volume, detects early fibrin strands, and visualizes multi-chambered loculations and septations without subjecting the child to ionizing radiation. [Persistent Fever / Deterioration after 48-72h of IV Antibiotics]

  • |
  • v
  • [Urgent Thoracic Ultrasound]
  • |
  • --------------------------------------------
  • | |
  • [Small, Simple Fluid; Child Stable] [Large/Enlarging or Complicated Effusion]
  • Continue targeted antibiotics - Assess respiratory compromise and ultrasound
  • Monitor clinical response - Ultrasound-guided chest drainage when indicated
  • Send drained fluid for microbiology
  • Fibrinolytics for loculated/thick infected fluid
  • |
  • [Persistent Sepsis/Compromise after 48-72h]
  • |
  • v
  • [Specialist Review for Rescue VATS]
  • Therapeutic Management

Antibiotics: Start IV treatment covering S. pneumoniae , S. pyogenes and S. aureus (e.g., cefotaxime/ceftriaxone plus flucloxacillin or clindamycin, guided by local resistance). Narrow to microbiology results. Switch to oral treatment when clinically improving with adequate drainage and oral tolerance; the total course , often 2–4 weeks, depends on response and residual disease.

Chest Tube Drainage with Intrapleural Fibrinolysis: For moderate-to-large effusions with respiratory distress or ultrasound-proven loculations, insert an ultrasound-guided small-bore intercostal pigtail catheter (8–14 Fr). Instill intrapleural fibrinolytics (e.g., urokinase twice daily for 3 days: 40,000 IU in 40 mL 0.9% saline at ≥1 year, or 10,000 IU in 10 mL under 1 year , under the local specialist protocol, or tissue plasminogen activator [alteplase/tPA] ). Fibrinolytics lyse fibrin cross-links, open loculations, clear the catheter, and restore drainage without the morbidity of open surgery.

Video-Assisted Thoracoscopic Surgery (VATS): Indicated when the lung remains trapped by an organized fibrous peel despite 72 hours of chest tube drainage and fibrinolytics, or in cases of multi-loculated organizing empyema where primary surgical debridement is elected.

Tip

Multiple randomized clinical trials comparing primary intrapleural fibrinolytics against primary VATS have demonstrated equivalent clinical efficacy, time to hospital discharge, and long-term pulmonary function, with intrapleural fibrinolytics conferring lower overall procedural morbidity and cost.

Cystic Fibrosis: Genetics, Pathophysiology, and Diagnostic Confirmation

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive genetic condition in European populations, occurring in approximately 1 in 2,500 to 3,500 live births.

Molecular Genetics and Pathophysiology

CF is caused by biallelic loss-of-function mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene on chromosome 7q31. The CFTR protein is an ATP-binding cassette phosphorylation-regulated chloride and bicarbonate channel expressed across apical membranes of exocrine epithelial cells.

The Delta-F508 (p.Phe508del) Mutation: Accounts for approximately 70% of CF alleles in European populations . It is a Class II processing mutation caused by a 3-base-pair deletion resulting in the loss of a phenylalanine residue at position 508. This causes protein misfolding in the endoplasmic reticulum, triggering targeted proteasomal degradation; virtually zero CFTR protein reaches the apical cell membrane.

Consequences in the Respiratory Epithelium: Lack of apical CFTR chloride secretion, combined with loss of inhibition on epithelial sodium channels ( ENaC ), drives massive, unchecked reabsorption of sodium and water from the airway lumen into epithelial cells. The resulting depletion of the periciliary liquid layer causes ciliary collapse, sticky mucus hypersecretion, impaired mucociliary clearance, chronic endobronchial bacterial infection, and bronchiectasis.

Diagnostic Pathways

Newborn Bloodspot Screening (NBS): Timing and follow-up algorithms are national; UK routine sampling is on day 5 . Screening measures immunoreactive trypsinogen (IRT) , a pancreatic enzyme precursor increased in many affected infants. A raised result leads to CFTR DNA testing and/or repeat IRT under the programme, followed by diagnostic assessment when indicated.

Confirmatory Sweat Chloride Testing (Pilocarpine Iontophoresis): The definitive diagnostic standard:

Sweat Chloride ≥60 mmol/L: Diagnostic of Cystic Fibrosis .

Sweat Chloride 30 to 59 mmol/L: Intermediate / Borderline . Repeat the sweat test and arrange CF-specialist clinical and CFTR genetic assessment. If the diagnosis remains inconclusive, consider validated nasal potential difference (NPD) or intestinal current measurement (ICM) testing at a specialist centre.

Sweat Chloride <30 mmol/L: Normal / Unlikely CF (except in rare atypical gating mutations).

Pulmonary Microbiology and Eradication Protocols in Cystic Fibrosis

CF lung disease is characterized by a predictable, age-dependent succession of bacterial endobronchial colonization: [Early Infancy & Toddlers]

  • Staphylococcus aureus (most common early pathogen)
  • Haemophilus influenzae (non-typeable)
  • |
  • v (Transition during early school age)
  • [Late Childhood, Adolescents & Adults]
  • Pseudomonas aeruginosa (Initial non-mucoid -> Chronic mucoid biofilm)
  • Burkholderia cepacia complex (Risk of fatal 'Cepacia Syndrome')
  • Stenotrophomonas maltophilia & Achromobacter xylosoxidans
  • Nontuberculous Mycobacteria (NTM: Mycobacterium abscessus)
  • Early Pseudomonas aeruginosa Eradication Protocol

Early Pseudomonas aeruginosa infection is often non-mucoid and susceptible to eradication. With persistent infection, adaptations including mucA mutations promote alginate production and a mucoid biofilm , protecting bacteria from host defences and antibiotics. Established chronic infection is much harder to eradicate and is associated with declining lung function.

Important

THE EARLY ERADICATION WINDOW: Treat the first positive surveillance respiratory culture promptly through the CF team, even when the child is asymptomatic. ECFS recommends starting preferably within 4 weeks . Do not wait for symptoms or lung-function decline.

Eradication Regimens:

Inhaled tobramycin 300 mg twice daily for 28 days is an established regimen and does not require routine oral ciprofloxacin.

An alternative is inhaled colistimethate sodium , commonly 1–2 million units twice daily, with oral ciprofloxacin according to the CF-centre protocol, potentially for up to 3 months. Ciprofloxacin doses commonly include 20–30 mg/kg/day in two doses; duration varies by protocol.

No single regimen is proven best. Early treatment often achieves high initial clearance (around 80–90% or more in trials), but recurrence occurs: obtain follow-up cultures to assess sustained eradication. Escalate failed eradication or a clinically unwell child with specialist advice.

Acute Pulmonary Exacerbations and Inpatient Management

Clinical Features: Increased cough frequency, changes in sputum production or purulence, new crackles, anorexia, weight loss, and a drop in spirometric F E V 1 FEV_1 FE V 1 ​ of ≥10% from baseline.

Antibiotic Selection: Obtain respiratory cultures and use prior microbiology and illness severity to choose treatment with the CF team. Milder exacerbations may be treated orally; significant Pseudomonas -associated illness commonly requires two IV agents from different classes . A reviewed IV course of 10–14 days is common, with duration adjusted to recovery rather than fixed for every exacerbation. Example specialist doses include:

Antipseudomonal Beta-Lactam: Ceftazidime (50 mg/kg every 8 hours, max 6 g/day) OR Piperacillin-Tazobactam ( piperacillin component 100 mg/kg every 6 hours, max 4 g per dose) OR Meropenem (40 mg/kg every 8 hours, max 2 g per dose).

Plus an Aminoglycoside: Once-daily Intravenous Tobramycin (8 to 10 mg/kg/day once daily). High renal clearance in CF requires elevated dosing and therapeutic drug monitoring (trough level <1.0 mg/L before the next dose to prevent nephrotoxicity and ototoxicity).

Mucociliary Clearance: Intensify airway clearance physiotherapy twice daily, preceded by recombinant human DNase (dornase alfa 2.5 mg nebulized) to digest extracellular DNA from degenerating neutrophils, and nebulized hypertonic 7% saline to hydrate airway surfaces.

Targeted Precision Medicine: CFTR Modulator Therapies

CFTR modulators represent a transformative therapeutic revolution that directly targets the underlying defect in protein processing and channel gating rather than treating downstream complications.

Modulator Agent Drug Class & Mechanism Target Mutation & Indications

Ivacaftor (Kalydeco) CFTR Potentiator: Binds directly to cell-surface CFTR channels to increase the channel open probability ( P o P_o P o ​ ), facilitating chloride and bicarbonate ion flow Class III Gating Mutations (e.g., G551D , S549N) and select residual function conductance mutations

Lumacaftor / Ivacaftor (Orkambi) Chaperone Corrector + Potentiator: Lumacaftor partially corrects F508del protein folding and cellular trafficking; ivacaftor opens surface channels Homozygous F508del/F508del (modest clinical efficacy; high drug interaction profile due to CYP3A induction)

Tezacaftor / Ivacaftor (Symkevi) Corrector + Potentiator: Improved pharmacokinetic profile and fewer drug interactions than lumacaftor Homozygous F508del/F508del or F508del with a residual function mutation

Elexacaftor / Tezacaftor / Ivacaftor (Kaftrio / Trikafta) Next-Generation Triple Combination: Dual correctors (elexacaftor and tezacaftor bind distinct sites to dramatically enhance F508del processing) plus ivacaftor potentiator EU: patients aged ≥2 years with at least one non-Class I CFTR mutation , including F508del; use the appropriate formulation and specialist genotype assessment

Clinical Impact of Triple Therapy (Elexacaftor/Tezacaftor/Ivacaftor)

In the EU, Kaftrio is used with additional ivacaftor from age 2 years for CF with at least one non-Class I CFTR mutation , including F508del; formulation and dosing depend on age and weight.

Compared with placebo, patients receiving triple therapy in the pivotal F508del/minimal-function trial at age ≥12 years had:

ppFEV1 (FEV1 as a percentage of predicted) 14.3 percentage points higher through 24 weeks (13.8 points at week 4), an absolute difference rather than a 14.3% relative increase in baseline FEV1.

Pulmonary exacerbation rate was 63% lower .

Sweat chloride was 41.8 mmol/L lower ; treatment may bring the value below the diagnostic threshold without removing the underlying CF diagnosis.

Nutrition and respiratory quality-of-life scores improved. These trial averages illustrate benefit; response varies with genotype, baseline disease and prior therapy.